NPS buys Samsung Biologics and SD Biosensor shares

By Kim, Jin-Gu | translator Alice Kang

22.07.11 06:00:48

가나다라 0

buys ₩140 billion of Samsung Biologics and ₩95 billion of SD Biosensor stocks… makes 18 net buys worth over ₩10 billion each

Net sells ₩54 billion of Yuhan Corp, ₩43 billion of SK Bioscience, and ₩27 billion of Bukwang Pharmaceutical stock

In the midst of the prolonged contraction observed in the Korean stock market, Korea’s largest institutional investor, the National Pension Service (NPS), was found to have expanded its investment in biotech/pharma companies by nearly ₩500 billion.

NPS net purchased ₩140 billion worth of Samsung Biologics shares and increased investment in SD Biosensor, Celltrion, Hanmi Pharmaceutical, Celltrion Healthcare, and Daewoong Pharmacuetical by over ₩50 billion. Also, NPS net sold over ₩50 billion worth of Yuhan Corp’s shares and over ₩40 billion worth of SK Bioscience shares during the same period.

◆NPS increases investment in Samsung Biologics and SD Biosen

Kim, Jin-Gu(kjg@dailypharm.com)

If you want to see the full article, please JOIN US (click)